XWELL (XWEL) Expected to Announce Earnings on Monday

XWELL (NASDAQ:XWEL) will likely be issuing its Q1 2026 resultson Monday, May 18th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $2.3710 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:00 PM ET.

XWELL (NASDAQ:XWEL) last issued its earnings results on Wednesday, April 1st. The company reported ($3.29) EPS for the quarter. The firm had revenue of $7.15 million during the quarter. XWELL had a negative return on equity of 352.37% and a negative net margin of 58.17%.

XWELL Price Performance

Shares of XWELL stock opened at $1.47 on Monday. XWELL has a 52-week low of $0.26 and a 52-week high of $2.20. The firm has a market capitalization of $11.66 million, a PE ratio of -0.29 and a beta of 1.01. The company’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $0.86.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on XWEL shares. Wall Street Zen upgraded XWELL from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded XWELL from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

XWELL Company Profile

XWELL, Inc provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels.